Cardiovascular

Latest News

Atrial fibrillation | image credit: Uladzlislau - stock.adobe.com

Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial

January 22nd 2025

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients with atrial fibrillation (AFib).

Breast cancer awareness graphic | image credit: ST.art - stock.adobe.com

Breast Cancer Stage May Influence Risk of Prevalent CVD

January 15th 2025

heart of pills-Denira-stock.adobe.com

Economic Data Show Cost-Effectiveness of Statin, Antihypertensive Polypill for CVD in Low-Income Populations

By Giuliana Grossi

January 14th 2025

Coffee | Image credit: dimakp - stock.adobe.com

Lower Risk of Cardiovascular Disease Mortality Associated With Morning Coffee

By Julia Bonavitacola

January 9th 2025

Cardiovascular top 5 of 2024 | Image Credit: Venngage

Top 5 Most-Read Cardiovascular Content of 2024

By Brooke McCormick

December 25th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights

Continuing Medical Education

January 24th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

January 24th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

January 24th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

May 16th 2016

A Cost-Effectiveness Analysis of Over-the-Counter Statins

Christopher Stomberg, PhD Margaret Albaugh, MA Saul Shiffman, PhD

This paper estimates the costs and benefits of over-the-counter (OTC) statins using data on statin use and cardiovascular risk, clinical studies of statin safety and efficacy, and an OTC statin use trial.

May 9th 2016

Potential of Risk-Based Population Guidelines to Reduce Cardiovascular Risk in a Large Integrated Health System

Galina Inzhakova, MPH Hui Zhou, PhD, MS Macdonald Morris, PhD Megan I. Early, MD, MPH Anny H. Xiang, PhD Steven J. Jacobsen, MD, PhD Stephen F. Derose, MD, MSHS

The authors evaluated the clinical applicability, accuracy, and implications of using an automated risk calculator and risk-based decision tool in an integrated health system.

April 3rd 2016

Data From North Carolina Out-of-Hospital Deaths Raise Many Questions

A small study of sudden out-of-hospital deaths raises questions about the quality of primary care, especially for women.

April 2nd 2016

Population Health Takes Center Stage to Open ACC

Greetings from First Lady Michelle Obama and a lecture from a non-cardiologist on population health set the stage for the 65th Scientific Session of the American College of Cardiology. Prevention is the focus of this year's meeting.

April 2nd 2016

Statins Can Cut Heart Attacks in Moderate-Risk Patients, Study Finds

Results from the HOPE-3 trial, presented on the opening day of the 65th Scientific Session of the American College of Cardiology, suggest cholesterol-lowering statins could have preventive benefits in broader groups of patients than previously thought.

March 21st 2016

Fewer Amputations, Hospital Deaths as Treatment Switches for Patients with Critical Limb Ischemia

The study from researchers at Cleveland Clinic found that during the years before full implementation of the Affordable Care Act, a shift in treatment methods for patients with a painful condition was associated with fewer amputations and deaths. But large disparities remain.

March 14th 2016

Inpatient and 90-Day Postdischarge Outcomes in Cardiac Surgery

Michael Pine, MD, MBA Susan M. Nedza, MD, MBA David G. Locke, BS Agnes M. Reband, BS Gregory Pine, BA

Coronary artery bypass grafting and cardiac valve surgery have dramatically different risk-adjusted outcomes over the 90 days following discharge, and demonstrate the opportunity for care improvement.

January 22nd 2016

High-Cost Patients Split in 3 Camps, Based on Insurance Status

The profile of high-cost patients in a Massachusetts ACO differed greatly, depending on their enrollment in Medicare, Medicaid, or a commercial plan.

January 13th 2016

No Association Found Between DPP-4 Inhibitors and Heart Failure in Review of Claims Data

Last year, an FDA advisory panel called for an updated label for saxagliptin, but the agency is still gathering information.

January 7th 2016

Most Americans Exceed Dietary Recommendations for Salt, CDC Finds

The findings on salt intake were timed to coincide with the release of the 2015 Dietary Guidelines for Americans.

December 4th 2015

CDC: Half of Those Eligible for Cholesterol Drugs Aren't Taking Them

Mary K. Caffrey

The estimate is based on the larger number of Americans now eligible to be treated for high LDL cholesterol, based on guidelines adopted in 2013.

December 3rd 2015

ELIXA Results on Lixisenatide Published in NEJM

Mary K. Caffrey

Results first presented at the American Diabetes Association in June are published. The new drug application has since been filed at FDA.

November 28th 2015

New Drug Application for Lixisenatide Accepted; CV Results Already in Hand

Mary K. Caffrey

Results from the ELIXA trial were presented in June at the 75th Scientific Sessions of the American Diabetes Association.

November 25th 2015

Mississippi to Pay for Bariatric Surgery to Combat Obesity

Mary K. Caffrey

The policy change is aimed at curbing the state's obesity rate as well as comorbidities such as diabetes

November 24th 2015

CVS Strikes Deal for Repatha Only; 18,000 Enroll in Long-term Praluent CV Outcomes Trial

Mary K. Caffrey

Terms of the deal with the second-largest pharmacy benefit manager were not disclosed. Pricing for the PCSK9 inhibitor class has been a source of controversy since the cholesterol-fighting drugs were approved this summer.

November 19th 2015

Study in Circulation Identifies 10 Biomarkers That Predict CV Events

Mary K. Caffrey

The study population took part in the landmark ORIGIN trial, which evaluated hypoglycemia effects in persons with high CV risk and diabetes.

November 11th 2015

Pooled Results Show Patients With and Without Diabetes Achieved Cholesterol Targets on Alirocumab

Results released by Sanofi and Regeneron of their PCSK9 inhibitor were based on prior clinical trials.

October 9th 2015

Medication Adherence and Healthcare Disparities: Impact of Statin Co-Payment Reduction

Jennifer Lewey, MD William H. Shrank, MD, MSHS Jerry Avorn, MD Jun Liu, MD, MPH Niteesh K. Choudhry, MD, PhD

This study examined patterns of medication adherence after a reduction in medication co-payment amount among privately insured patients living in racially diverse neighborhoods.

September 29th 2015

Lixisenatide New Drug Application Accepted for Review With CV Results Already in Hand

Mary K. Caffrey

Results presented at the American Diabetes Association in June showed no CV risk or benefit and no risk of pancreatic injury, an issue that has been of particular concern to FDA.

September 28th 2015

Behavioral Health at Heart of Recommended Medicaid Measures From National Quality Forum

Mary K. Caffrey

The recommendations for improving quality care in Medicaid track recent trends in psychiatric and diabetes care, which recognize the connection between physical and mental health.

August 27th 2015

Personalizing Care in Hypertensive Patients Improves Adherence and Outcomes

Surabhi Dangi-Garimella, PhD

A stepped care algorithm developed by scientists has the potential to manage blood pressure in patients who develop intolerance to guideline-based regimens.

August 5th 2015

Review of Amgen Cholesterol Drug Favored by FDA Panel

Michael R. Page, PharmD, RPh

An overview of mechanism of action, dosing, interactions, and precautions for evolocumab, which faces an FDA deadline for review August 27, 2015.

August 3rd 2015

New Tool for the Early Diagnosis of Cardiometabolic Disease

Surabhi Dangi-Garimella, PhD

A study published in the American Journal of Preventive Medicine shows that grip strength of young, healthy adults could prove useful in the diagnosis of diabetes and hypertension.

July 30th 2015

Praluent: A Fair Price or Wreaking "Havoc" in Health Plans?

Mary K. Caffrey

Earnings calls over the past 2 days for Express Scripts and Sanofi offered starkly different views of pricing for the first PCSK9 inhibitor to reach the US market.

July 27th 2015

So Praluent Is Approved. The Question Now Is, Who Gets It?

Mary K. Caffrey

Health plans and pharmacy benefits managers are expected to scrutinize the FDA approval to ensure that only those patients who truly need the drug get it.Drugmakers say discounts will cause the price to fall below the $14,600 annual wholesale price listed.

July 14th 2015

Newer Cholesterol Guidelines Prove Beneficial and Cost-Effective

The American College of Cardiology and the American Heart Association's release of recommendations for statin treatment in the prevention of cardiovascular disease (CVD) in 2013 have now proven both cost-effective and accurate in identifying CVD risk.

July 12th 2015

ACA Coverage Expansion Expected to Reduce Cardiovascular Deaths

CDC report estimates that the Affordable Care Act could lead to 111,000 fewer new coronary heart disease events and 95,000 fewer CVD-related deaths by 2050.

July 2nd 2015

More Than Half of Cardiovascular Deaths Are Preventable

Laura Joszt, MA

Cardiovascular disease may be the leading cause of death in the United States, but half of those deaths can be prevented, according to researchers from Emory's Rollins School of Public Health.

June 9th 2015

ELIXA Trial Results Find No Cardiac Risk, Benefit for Lixisenatide

Mary K. Caffrey

Results are the first from a cardiovascular safety trial in the GLP-1 agonist class. A commentator at the 75th Scientific Sessions of the American Diabetes Association asked whether the FDA-mandated studies are giving physicians the right information.

June 9th 2015

Sitagliptin Does Not Cause Adverse Cardiovascular Effects, TECOS Trial Finds

Mary K. Caffrey

The long-awaited results, presented Monday at the 75th Scientific Sessions of the American Diabetes Association, are expected to strengthen sitagliptin's position against its competitors in the DPP-4 inhibitor class.

...

15 16 17 18 19 20 21 22 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions